Budget Impact Analysis of Revumenib for the Treatment of Relapsed or Refractory (R/R) NPM1-Mutated Acute Myeloid Leukemia (AML) in the United States

Poster Presentation | Apr 13, 2026

Author

Abraham I, et al.

Congress

Academy of Managed Care Pharmacy (AMCP) Annual Meeting

Nashville, TN | Apr 13 – 16, 2026